Cardiovascular Diseases
The Centro Hospitalar E Universitario De Coimbra E.P.E. Neurology department is conducting research aimed at preventing and treating cerebrovascular events, with a focus on acute ischemic stroke and high‑risk transient ischemic attack. A key study evaluates the safety and efficacy of milvexian to lower the risk of recurrent stroke.
- Acute Ischemic Stroke
- High‑Risk Transient Ischemic Attack
- Antithrombotic Therapy Development
- Risk Reduction Strategies
Investigators are exploring novel anticoagulant approaches to improve outcomes for patients at high risk of cardiovascular complications.
Nervous System Diseases
In the realm of neurodegenerative and epileptic disorders, the site is testing innovative therapies for Alzheimer’s disease and primary generalized tonic‑clonic seizures. One trial measures amyloid reduction with ABBV‑916 in early Alzheimer’s, while another assesses the impact of XEN1101 on seizure frequency.
- Early Alzheimer’s Disease
- Amyloid Targeting Strategies
- Primary Generalized Tonic‑Clonic Seizures
- Seizure Frequency Reduction
The multidisciplinary team aims to bring disease‑modifying treatments to patients with cognitive decline and epilepsy.
Virus Diseases
The hospital participates in an adaptive platform trial addressing COVID‑19, evaluating therapeutic options for both moderate and severe disease. A specific protocol compares baricitinib plus standard of care against placebo in immunocompromised patients with critical illness.
- Moderate COVID‑19
- Severe/Critical COVID‑19
- Adaptive Pandemic Platform
- Immunocompromised Patient Care
These efforts contribute to global knowledge on effective interventions during the pandemic and support vulnerable patient groups.
